Opening book details…
Can I read Combination Chemotherapy with Methotrexate, Bleomycin, and Vincristine with or Without Cisplatin in Advanced Squamous Cell Carcinoma of the Head and Neck on EtoBox?
Combination Chemotherapy with Methotrexate, Bleomycin, and Vincristine with or Without Cisplatin in Advanced Squamous Cell Carcinoma of the Head and Neck by M. Clavel; F. Cognetti; P. Dodion; J. Wildiers; R. Rosso; A. Rossi; B. Gignoux; M. Van Rymenant; H. Cortes-Funes; O. Dalesio; A. Kirkpatrick; M. Rozencweig is a Medicine article available to read on EtoBox.
What is Combination Chemotherapy with Methotrexate, Bleomycin, and Vincristine with or Without Cisplatin in Advanced Squamous Cell Carcinoma of the Head and Neck about?
## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methotrexate (40 mg/mf days 1,15), bleomycin (10 mg; days 1,8, and 15), and vincristine (2 mg; days 1,8, and 15) and the ABO group received methotrexate, bleomycin and vincristine in the same doses on days 1, 8, and 15. After three courses, patients in both arms received weekly methotrexate as maintenance therapy; those 34 patients with previously untreated locoregional disease went off the study because of subsequent locoregional treatment in form of radiotherapy f surgery. The complete response rate was 16% in patients receiving CABO, compared with 5% among patients given ABO. The corresponding overall response rates were 50% and 28%, respectively (P = 0.003). Among patients with recurrent or metastatic disease, progression was delayed in patients receiving CABO (median, 18 weeks) compared to those receiving ABO (median, 14 weeks) (P = 0.07), but there was no difference in survival time. Myelo
Who reads Combination Chemotherapy with Methotrexate, Bleomycin, and Vincristine with or Without Cisplatin in Advanced Squamous Cell Carcinoma of the Head and Neck?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- M. Clavel; F. Cognetti; P. Dodion; J. Wildiers; R. Rosso; A. Rossi; B. Gignoux; M. Van Rymenant; H. Cortes-Funes; O. Dalesio; A. Kirkpatrick; M. Rozencweig
- Publisher
- John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)
- Published
- 1987
- Language
- EN
- Field
- Medicine (Health Sciences)